ALG1001

Research use only, not for human use.

ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (αvβ3, αvβ5, and α5β1) associated with angiogenesis.

ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (αvβ3, αvβ5, and α5β1) associated with angiogenesis; ALG1001 inhibits an integrin-mediated pathway of the vitreoretinal interface, connecting the posterior aspect of the vitreous with the internal limiting membrane of the retina. In blocking this pathway, ALG-1001 helps to achieve vitreous breakdown and separation from the retina.

——

——

Risuteganib | ALG 1001 | ALG-1001

Cell Cycle/DNA Damage

Integrin

Integrin

Other Indications

Other Disease

1307293-62-4

637.666

C22H39N9O11S

>98% (HPLC)

——

O=C(O)[C@H]1N(C([C@H]([C@H](O)C)NC([C@H](CS(=O)(O)=O)NC(CNC([C@H](CCCNC(N)=N)NC(CN)=O)=O)=O)=O)=O)CCC1

L-Proline, glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl-

(-20℃)

With Ice Pack

≥ 2 years